Xiaomei Yuan

Director @ Sorrento Therapeutics, Inc.

Country

United States

City

San Diego

Industry

Research

Skill

Research and Development (R&D), Management, Immunology, Cell Therapy, CAR-T, CAR-NK, iPSC, Flow Cytometry, Cell Based Assays, Cell Culture, in vivo, Immunofluorescence, Transfection, Reverse Transcription Polymerase Chain Reaction (RT-PCR), Molecular Cloning, ELISA, WESTERN BLOT, Autoimmunity, Immune Regulation, Tolerance

Experience

Director

Sorrento Therapeutics, Inc.

2021-3 - Present · 5 yrs 7 mos

CAR-T and iPSC CAR-NK cell therapy

Senior Scientist/Associate Director

Sorrento Therapeutics, Inc.

2020-4 - 2021-3 · 1 yr

San Diego, California, United States

CAR-T immunotherapy

Scientist

Sorrento Therapeutics, Inc.

2018-9 - 2020-4 · 1 yr 8 mos

San Diego

CAR-T immunotherapy

Postdoctoral Research Fellow

UC San Diego Health

2014-6 - 2018-7 · 4 yrs 2 mos

• Investigated the function of CRIg+ macrophages in T1D and the role of CRIg, as a coinhibitory molecule in regulating T cell responses. Furthermore, to investigate the role of CRIg in tumor immunotherapy using liver cancer model. • Examined the function of a monoclonal antibody to CD122 which modulates IL-2 receptor signaling to restore immune tolerance and further to treat T1D. • Identify the role of SHP2 in regulatory T cells. • Investigate the role of IL-33 in T1D.

Graduate Student

University of Miami Miller School of Medicine

2008-8 - 2014-4 · 5 yrs 9 mos

• Examined the role of IL-2 receptor dependent signaling and CD103 in regulatory T cells for gut mucosal tolerance. • Defined the function and significance of regulatory T cell subsets, i.e. naïve, effector and memory regulatory T cell subsets. • Defined the role of transcription factor Blimp-1 in the development of regulatory T cell subsets.

Graduate Student

Huazhong University of Science and Technology

2004-9 - 2007-6 · 2 yrs 10 mos

• Investigated somatostatin receptor subtype 2 mediated effects in breast cancer cell line. • Participated in tumor immunotherapy projects that involved improving tumor cell immunogenicity, including applying HSV-TK/GCV as an adjuvant in tumor cells to improve dendritic cell (DC) vaccination, and introducing CCL21 in cancer cells to enhance DC function.